Oragenics, Inc. OGEN 深 沪
等待开盘 05-27 09:30:00 美东时间
0.5923
-0.005
-0.79%
华盛通- 最 高0.60
- 今 开0.60
- 成交量 4.16万股
- 最 低 0.5801
- 昨 收 0.597
- 总市值 267.24万
- 52周最高 7.60
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 0.5038
- 委 比 33.33%
- 总股本 451.20万
- 历史最高 83700.00
- 量 比 1.04
- 振 幅 3.33%
- 历史最低 0.5038
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oragenics Highlights Investor Outreach at Micro-Cap Conference
The latest update is out from Oragenics ( ($OGEN) ). On May 18, 2026, Oragenics...
05-19 20:58
Oragenics presents at Sidoti Micro-Cap Virtual Investor Conference
Oragenics presents at Sidoti Micro-Cap Virtual Investor Conference Oragenics will present at Sidoti’s Micro-Cap Virtual Investor Conference on May 21, 2026, with the webcast scheduled for 3:15 p.m. ET. Virtual one-on-one investor meetings are set for May 20-21, 2026. Disclaimer: This news brief was
05-19 20:45
Oragenics begins dosing in Australia Phase IIa ONP-002 concussion trial
Oragenics begins dosing in Australia Phase IIa ONP-002 concussion trial Oragenics started enrolling and dosing patients in its Phase IIa, placebo-controlled feasibility study of intranasal concussion treatment ONP-002 in Australia, with a 40-patient target. Early execution signals included site acti
05-18 20:33
Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.
05-09 06:14
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San Diego, CA, May 07,
05-07 20:34
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage
04-20 21:04
Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
04-13 20:34
Oragenics Sets New 2025 Annual Shareholder Meeting Date
The latest update is out from Oragenics ( ($OGEN) ). On March 27, 2026, Orageni...
04-01 07:45
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics, Inc. announced that its audited consolidated financial statements for the year ended December 31, 2025, include an unqualified audit opinion with a going concern explanatory paragraph. The Annual Report on Form 10-K, filed on March 16, 2026, is available on the SEC's EDGAR system and the company's investor relations website. The company specializes in brain-targeted therapeutics via proprietary intranasal delivery technology, focusing ...
03-25 22:30
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics, Inc. reported significant progress in 2025, transitioning to a focused biotech company with key milestones including NYSE compliance, clinical trial advancements, manufacturing shift to the U.S., and AI partnerships. The company raised $16.5 million, repaid debt, and reduced expenses. In early 2026, they secured ethics approval, initiated trial sites, and prepared for U.S. clinical activities. Priorities for 2026 include completing Pha...
03-17 12:30
